Bupropion is not licensed as an antidepressant in the UK, limiting its use. We highlight bupropion's distinct pharmacological profile and its potential benefits in treatment-resistant depression and people experiencing selective serotonin reuptake inhibitor-induced sexual dysfunction. The National Health Service repurposing medicines programme could improve equity of access for UK patients.
Journal article
Br J Psychiatry
03/04/2025
1 - 3
Bupropion, depression, inflammation, licensing, sexual dysfunction